<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00875784</url>
  </required_header>
  <id_info>
    <org_study_id>103629</org_study_id>
    <nct_id>NCT00875784</nct_id>
  </id_info>
  <brief_title>An Open-label, Randomized, 3-period Crossover Study to Evaluate Sumatriptan Pharmacokinetics for a TREXIMA™ (Sumatriptan Succinate / Naproxen Sodium) Tablet Followed by IMITREX® (Sumatriptan Succinate)</brief_title>
  <official_title>An Open-label, Randomized, 3-period Crossover Study to Evaluate Sumatriptan Pharmacokinetics for a TREXIMA™ (Sumatriptan Succinate / Naproxen Sodium) Tablet Followed by IMITREX® (Sumatriptan Succinate) Injection 4mg Administered Using the IMITREX STATdose System® and a TREXIMA Tablet Followed by IMI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the exposure of sumatriptan after administration of TREXIMA
      (sumatriptan 85mg/naproxen sodium 500mg) followed by a subcutaneous IMITREX injection (4mg or
      6mg) 2 hours later compared to administration of a IMITREX 100mg tablet followed by a IMITREX
      100mg tablet 2 hours later.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label, randomized, 3-period crossover study to evaluate sumatriptan pharmacokinetics
      for a TREXIMA™ (sumatriptan succinate / naproxen sodium) Tablet followed by IMITREX®
      (sumatriptan succinate) Injection 4mg administered using the IMITREX STATdose System® and a
      TREXIMA tablet followed by IMITREX® (sumatriptan succinate) Injection 6mg administered using
      the IMITREX STATdose System® compared with an IMITREX Tablet 100mg followed by an IMITREX
      Tablet 100mg.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 6, 2008</start_date>
  <completion_date type="Actual">June 14, 2008</completion_date>
  <primary_completion_date type="Actual">June 14, 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The maximum plasma concentration (Cmax) after the second dose and total exposure (measured by AUC(0-∞) calculated as pooled exposure from both the initial and second dose).</measure>
    <time_frame>ten weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events, blood pressure, pulse, ECGs and clinical laboratory tests.</measure>
    <time_frame>ten weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Migraine Disorders</condition>
  <arm_group>
    <arm_group_label>TREXIMA tablet followed by IMITREX injection (4mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TREXIMA™ (sumatriptan succinate / naproxen sodium) Tablet followed by IMITREX® (sumatriptan succinate) Injection 4mg administered using the IMITREX STATdose System®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TREXIMA tablet followed by IMITREX injection (6mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TREXIMA tablet followed by IMITREX® (sumatriptan succinate) Injection 6mg administered using the IMITREX STATdose System®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMITREX tablet (100mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IMITREX 100mg tablet followed 2 hours later by a second IMITREX 100mg tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TREXIMA™</intervention_name>
    <description>sumatriptan succinate / naproxen sodium tablet</description>
    <arm_group_label>TREXIMA tablet followed by IMITREX injection (6mg)</arm_group_label>
    <arm_group_label>TREXIMA tablet followed by IMITREX injection (4mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMITREX® (4mg)</intervention_name>
    <description>sumatriptan succinate injection (4mg) administered using the IMITREX STATdose System®</description>
    <arm_group_label>TREXIMA tablet followed by IMITREX injection (4mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMITREX® (6mg)</intervention_name>
    <description>sumatriptan succinate injection (6mg) administered using the IMITREX STATdose System®</description>
    <arm_group_label>TREXIMA tablet followed by IMITREX injection (6mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMITREX Tablet 100mg</intervention_name>
    <description>IMITREX 100mg tablet followed 2 hours later by a second IMITREX 100mg tablet</description>
    <arm_group_label>IMITREX tablet (100mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult males and females between 18 and 55 years of age, inclusive. Healthy
             subjects are defined as individuals who are free from clinically significant illness
             or disease as determined by their medical history, physical examination, laboratory
             studies and other tests.

          -  Female subjects of non-childbearing potential

          -  Any subject taking oral contraceptives has been on a stable regimen for at least 2
             months prior to screening.

          -  BMI: 20-30 kg/m2, inclusive.

          -  Subject is willing and able to provide written informed consent.

        Exclusion Criteria:

          -  Subjects who suffer from migraine attacks.

          -  Subject has confirmed or suspected ischemic heart disease; angina pectoris, history of
             myocardial infarction, documented silent ischemia, Prinzmetal's angina-coronary
             vasospasm, signs, or symptoms consistent with any of the above.

          -  Subject has evidence or history of ischemic abdominal syndromes, peripheral vascular
             disease or Raynaud's syndrome.

          -  Subject has cardiac arrhythmias requiring medication or a history of a clinically
             significant electrocardiogram abnormality that, in the investigator's opinion,
             contraindicates participation in this study.

          -  Subject has a history of cerebrovascular pathology including stroke and/or transient
             ischemic attacks.

          -  Subject has a history of congenital heart disease.

          -  Subject has hypertension at screening.

          -  Subject, in the investigator's opinion, is likely to have unrecognized cardiovascular
             or cerebrovascular disease.

          -  Subject has a history of epilepsy or structural brain lesions which lower the
             convulsive threshold or treated with an antiepileptic drug for seizure control within
             5 years prior to screening.

          -  History of impaired hepatic or renal function.

          -  Subject is currently taking or has taken in the previous 4 weeks, herbal preparations
             containing St. John's Wort.

          -  Use of other prescription or non-prescription drugs, vitamins, herbal and dietary
             supplements, within 7 days prior to the first dose of study medication.

        Note: Excluded from this list are: acetaminophen at doses of less than or equal to 2 grams
        per day and contraceptives.

          -  Subject has a hypersensitivity, intolerance, or contraindication to the use of
             sumatriptan or naproxen sodium or any of their components or any other 5-HT1 receptor
             agonist.

          -  Subject has a history of any gastrointestinal surgery that specifically indicates a
             past history of bleeding, ulceration or perforation.

          -  Subject has a history of gastric bypass or stapling surgery.

          -  Subject has a history of GI ulceration in the past six months or gastrointestinal
             bleeding in the past year.

          -  Subject has a history of inflammatory bowel disease.

          -  Treatment with an investigational drug within 30 preceding the first dose of study
             medication.

          -  Positive serum beta-human chorionic gonadotropin test -females.

          -  Pregnant, actively trying to become pregnant or breast-feeding.

          -  Subjects with a history of drug or alcohol abuse.

          -  History of regular alcohol consumption exceeding 7 drinks per week for females or 14
             drinks per week for men within 6 months of screening.

          -  Positive urine drug screen including alcohol at screening.

          -  Donation of blood in excess of 500 mL within 56 days prior to first dose of study
             medication.

          -  Subjects who smoke more than 10 cigarettes per day.

          -  History of sensitivity to heparin, heparin-induced thrombocytopenia or sensitivity to
             any of the study medications or components thereof.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <link>
    <url>https://gsk-clinicalstudyregister.com/study/103629?search=study&amp;study_ids=103629#rs</url>
    <description>Results for study 103629 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2009</study_first_submitted>
  <study_first_submitted_qc>April 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2009</study_first_posted>
  <last_update_submitted>August 3, 2017</last_update_submitted>
  <last_update_submitted_qc>August 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sumatriptan exposure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Sumatriptan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>103629</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>103629</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>103629</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>103629</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>103629</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>103629</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>103629</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

